Compston J. Glucocorticoid-induced osteoporosis: an update. Endocrine. 2018;61:7–16.

CAS  PubMed  PubMed Central  Google Scholar 

Compston JE. Extensive expertise in endocrinology: advances in the management of glucocorticoid-induced osteoporosis. Eur J Endocrinol. 2023;188:R46–55.

CAS  PubMed  Google Scholar 

Balasubramanian A, Wade SW, Adler RA, Lin CJF, Maricic M, O’Malley CD, et al. Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis. Osteoporos Int. 2016;27:3239–49.

CAS  PubMed  Google Scholar 

Gregson CL, Armstrong DJ, Bowden J, Cooper C, Edwards J, Gittoes NJL, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2022;17:58.

PubMed  PubMed Central  Google Scholar 

Trijau S, De Lamotte G, Pradel V, Natali F, Allaria-Lapierre V, Coudert H, et al. Osteoporosis prevention among chronic glucocorticoid users: results from a public health insurance database. RMD Open. 2016;2:e000249.

PubMed  PubMed Central  Google Scholar 

Majumdar SR, Lix LM, Morin SN, Yogendran M, Metge CJ, Leslie WD. The Disconnect Between Better Quality of Glucocorticoid-induced Osteoporosis Preventive Care and Better Outcomes: A Population-based Cohort Study. J Rheumatol. 2013;40:1736–41.

CAS  PubMed  Google Scholar 

Silverman S, Curtis J, Saag K, Flahive J, Adachi J, Anderson F, et al. International management of bone health in glucocorticoid-exposed individuals in the observational GLOW study. Osteoporos Int. 2015;26:419–20.

CAS  PubMed  Google Scholar 

Hart SR, Green B. Osteoporosis prophylaxis during corticosteroid treatment: failure to prescribe. Postgrad Med J. 2002;78:242–3.

CAS  PubMed  PubMed Central  Google Scholar 

Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, et al. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol. 2021;185:G43–67.

CAS  PubMed  Google Scholar 

Burch HB, Perros P, Bednarczuk T, Cooper DS, Dolman PJ, Leung AM, et al. Management of Thyroid Eye Disease: A Consensus Statement by the American Thyroid Association and the European Thyroid Association. Thyroid. 2022;32:1439–70.

PubMed  PubMed Central  Google Scholar 

Perros P, Žarković M, Azzolini C, Ayvaz G, Baldeschi L, Bartalena L, et al. PREGO (presentation of Graves’ orbitopathy) study: changes in referral patterns to European Group On Graves’ Orbitopathy (EUGOGO) centres over the period from 2000 to 2012. Br J Ophthalmol. 2015;99:1531–5.

PubMed  Google Scholar 

Bartalena L, Piantanida E, Gallo D, Lai A, Tanda ML. Epidemiology, Natural History, Risk Factors, and Prevention of Graves’ Orbitopathy. Front Endocrinol. 2020;11:615993.

Google Scholar 

National Institute of Clinical Excellence. Equivalent anti-inflammatory doses of oral corticosteroids [Internet]. 2025 [cited 2025 Jun 14]. Available from: https://cks.nice.org.uk/topics/corticosteroids-oral/background-information/equivalent-anti-inflammatory-doses/

Delitala AP, Scuteri A, Doria C. Thyroid Hormone Diseases and Osteoporosis. J Clin Med. 2020;9:1034.

CAS  PubMed  PubMed Central  Google Scholar 

National Osteoporosis Guideline Group. Clinical guideline for the prevention and treatment of osteoporosis [Internet]. 2024 [cited 2025 Jun 10]. Available from: https://www.nogg.org.uk/full-guideline

National Institute of Clinical Excellence. Osteoporosis - prevention of fragility fractures. 2025.

British National Formulary. Alendronic acid [Internet]. [cited 2025 Jun 14]. Available from: https://bnf.nice.org.uk/drugs/alendronic-acid/

Yanbeiy ZA, Hansen KE. Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis. Drug Des Devel Ther. 2019;13:2843–52.

CAS  PubMed  PubMed Central  Google Scholar